Custom service
Custom Peptide Inhibitors Synthesis Service
Synthesize peptide inhibitors — protease, kinase, peptidomimetic — with potency-oriented design
Custom Peptide Inhibitors Synthesis Service supports programmes that synthesize peptide inhibitors — protease, kinase, peptidomimetic — with potency-oriented design. In a typical engagement we plan the warhead and electrophile installation route first, confirm compatibility with transition-state mimic assembly, and release inhibitor panel with purity and design notes on a 3–7 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep warhead and electrophile installation as the primary option and hold transition-state mimic assembly in reserve, so that scale-up never depends on an unproven step.
Protease inhibitor panels (DPP4, MMP, caspase classes)
Allosteric and substrate-mimetic inhibitors
Potency testing against live pathogens
Sequences where a recombinant expression route is objectively cheaper and faster
Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.
Service Highlights
- Warhead and electrophile installation as the default route, with transition-state mimic assembly held as a proven fallback
- D-residue and N-methyl stabilization worked into the design where the application requires it
- Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
- Analytical confirmation of every intermediate before the final release
- Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
- Inhibitor panel with purity and design notes delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence analysis
Custom Peptide Inhibitors Synthesis Service is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.
Route selection
Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.
Assembly
The chain is built with warhead and electrophile installation applied where the sequence demands it, with double-coupling at hazard sites.
Cleavage & crude QC
Crude material is characterized so purification targets are set on data, not hope.
Purification
RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.
Release
Inhibitor panel with purity and design notes is documented with the full analytical package and released.
Specifications & timeline
- Turnaround
- 3–7 weeks
- Typical scale
- 0.1 mg – 10 g per sequence
- Chemistry options
- warhead and electrophile installation; transition-state mimic assembly; D-residue and N-methyl stabilization
- Deliverable
- Inhibitor panel with purity and design notes
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
- Shipping
- Ambient with desiccant; blue ice for modified or sensitive peptides
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.